|
[1]Arroyo V, Terra C, Gines P.Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome[J].J Hepatol, 2007, 46 (5) :935-946.
|
|
[2]中华医学会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 19 (1) :56-62.
|
|
[3]Salern F, Gerbes A, Gines P, et al.Diagnosis, prevention and treatment of hepatorenal syndrome with cirrhosis[J].Gut, 2007, 56 (9) :1310-1318.
|
|
[4]Angemary B, Ceina M, Karnel F, et al.Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemie shunt[J].Gut, 2003, 56 (2) :879-885.
|
|
[5]García-Paqan JC, Caca K, Bureau C, et al.Early use of TIPS in Patients with cirrhosis and variceal bleeding[J].N Engl J Med, 2010, 362 (25) :2370-2379.
|
|
[6]Cardenas A, Gines P.Hepatorenal syndrome[J].Clin Liver Dis, 2006, 10 (2) :371-385.
|
|
[7]Wong F, Moore K, Dingemanse J, et al.Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type-2 hepatorenal syndrome[J].Hepatology, 2008, 47 (1) :160-168.
|
|
[8]Fernández J, Monteagudo J, Bargallo X, et al.A randomized unblended pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis[J].Hepatology, 2005, 42 (3) :627-634.
|
|
[9]Sanyal AJ, Boyer T, Garcia-Tsao G, et al.A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type1 hepatorenal syndrome[J].Gastroenterology, 2008, 134 (5) :1360-1368.
|
|
[10]Krag A, Bendtsen F, Henriksen JH, et al.Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites[J].Gut, 2010, 59 (1) :105-110.
|
|
[11]Moore KP, Aithal GP.Guidelines on the management of ascites in cirrhosis[J].Gut, 2006, 55 (Suppl 6) :vi1-12.
|
|
[12]Rssle M, Gerbes AL.TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax:a critical update[J].Gut, 2010, 59 (7) :988-1000.
|